Shock Therapeutics Biotechnologies Information

Over 5 million people die annually from trauma, tragically threatening the lives of millions more. Shock Therapeutics Biotechnologies, Inc. was founded by Dr. Donald Gann and Dr. Dan Darlington to bring to market a revolutionary new approach to shock treatment, which preliminary evidence suggests may significantly extend the opportunity to provide critical care. Backed by an innovative team ready to tackle the challenges ahead, STBI is positioned to revolutionize the treatment of shock. We are seeking financial support and strategic partners to help us complete the final preclinical testing needed to develop our Shock Antibody™ over the next 2-3 years and prepare for human clinical trials. Feel free to contact us at info@shockbiotech.com to learn more!